{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:11:24Z","timestamp":1782450684406,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,15]]},"DOI":"10.7759\/cureus.90150","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T13:33:08Z","timestamp":1755264788000},"source":"Crossref","is-referenced-by-count":3,"title":["Empagliflozin and Cardiovascular Outcomes: A Systematic Review of Randomized Controlled Trials in Populations With Diabetes and Heart Failure"],"prefix":"10.7759","author":[{"given":"Farrukh","family":"Ansar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeeh","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima K","family":"Ghauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdulRehman M","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafay","family":"Mehmood Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdah","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rehman","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1288","article-title":"The heart of the world","volume":"19","author":"Di Cesare M","year":"2024","unstructured":"Di Cesare M, Perel P, Taylor S, et al.. The heart of the world. Glob Heart. 2024, 19:10.5334\/gh.1288","journal-title":"Glob Heart"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson TR","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018, 17:10.1186\/s12933-018-0728-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S002","article-title":"Classification and diagnosis of diabetes: standards of care in diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023, 46:19-40. 10.2337\/dc23-S002","journal-title":"Diabetes Care"},{"key":"ref4","article-title":"IDF Diabetes Atlas. Tenth Edition","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ. IDF Diabetes Atlas. Tenth Edition. International Diabetes Federation, Brussels, BE; 2021."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001951","article-title":"Determinants of cardiovascular disease among type 2 diabetic patients attending diabetic follow-up clinic in Arba Minch general hospital, southern Ethiopia: an unmatched case-control study","volume":"86","author":"Annose RT","year":"2024","unstructured":"Annose RT, Asefa H, Gezahagn Y, Abebe G, Zewde TH. Determinants of cardiovascular disease among type 2 diabetic patients attending diabetic follow-up clinic in Arba Minch general hospital, southern Ethiopia: an unmatched case-control study. Ann Med Surg (Lond). 2024, 86:2467-73. 10.1097\/MS9.0000000000001951","journal-title":"Ann Med Surg (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.544312","article-title":"Cardiovascular complications of diabetes mellitus in sub-Saharan Africa","volume":"112","author":"Kengne AP","year":"2005","unstructured":"Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in sub-Saharan Africa. Circulation. 2005, 112:3592-601. 10.1161\/CIRCULATIONAHA.105.544312","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02026-9","article-title":"Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study","volume":"22","author":"Pei J","year":"2023","unstructured":"Pei J, Wang X, Pei Z, Hu X. Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study. Cardiovasc Diabetol. 2023, 22:10.1186\/s12933-023-02026-9","journal-title":"Cardiovasc Diabetol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry RJ","year":"2020","unstructured":"Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020, 295:14379-90. 10.1074\/jbc.REV120.008387","journal-title":"J Biol Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46243","article-title":"Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management","volume":"15","author":"Fatima A","year":"2023","unstructured":"Fatima A, Rasool S, Devi S, et al.. Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management. Cureus. 2023, 15:10.7759\/cureus.46243","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14626","article-title":"The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease","volume":"24","author":"Kaku K","year":"2022","unstructured":"Kaku K, Wanner C, Anker SD, Pocock S, Yasui A, Mattheus M, Lund SS. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. Diabetes Obes Metab. 2022, 24:662-74. 10.1111\/dom.14626","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1135900","article-title":"A safety evaluation of empagliflozin for the treatment of type 2 diabetes","volume":"15","author":"Neeland IJ","year":"2016","unstructured":"Neeland IJ, Salahuddin U, McGuire DK. A safety evaluation of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Saf. 2016, 15:393-402. 10.1517\/14740338.2016.1135900","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler J","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, et al.. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024, 390:1455-66. 10.1056\/NEJMoa2314051","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego CG","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al.. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021, 77:243-55. 10.1016\/j.jacc.2020.11.008","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee MM","year":"2021","unstructured":"Lee MM, Brooksbank KJ, Wetherall K, et al.. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021, 143:516-25. 10.1161\/CIRCULATIONAHA.120.052186","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma S","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, et al.. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019, 140:1693-702. 10.1161\/CIRCULATIONAHA.119.042375","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi NA","year":"2020","unstructured":"Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial. Circulation. 2020, 142:1713-24. 10.1161\/CIRCULATIONAHA.120.048739","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski D","year":"2022","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ, et al.. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022, 43:4421-32. 10.1093\/eurheartj\/ehac494","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu W","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, et al.. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020, 19:10.1186\/s12933-020-01127-z","journal-title":"Cardiovasc Diabetol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen J","year":"2020","unstructured":"Jensen J, Omar M, Kistorp C, et al.. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. Am Heart J. 2020, 228:47-56. 10.1016\/j.ahj.2020.07.011","journal-title":"Am Heart J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02756-y","article-title":"Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial","volume":"24","author":"Ovchinnikov A","year":"2025","unstructured":"Ovchinnikov A, Potekhina A, Filatova A, Svirida O, Zherebchikova K, Ageev F, Belyavskiy E. Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial. Cardiovasc Diabetol. 2025, 24:10.1186\/s12933-025-02756-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85669","article-title":"Effect of empagliflozin on cardiovascular mortality and heart failure hospitalizations: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Rauf U","year":"2025","unstructured":"Rauf U, Ansar F, Ali MS, et al.. Effect of empagliflozin on cardiovascular mortality and heart failure hospitalizations: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2025, 17:10.7759\/cureus.85669","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091463","article-title":"Left ventricular unloading in acute on chronic heart failure: from statements to clinical practice","volume":"12","author":"Sacco A","year":"2022","unstructured":"Sacco A, Morici N, Oreglia JA, et al.. Left ventricular unloading in acute on chronic heart failure: from statements to clinical practice. J Pers Med. 2022, 12:10.3390\/jpm12091463","journal-title":"J Pers Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"Borovac JA","year":"2020","unstructured":"Borovac JA, D'Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers. World J Cardiol. 2020, 12:373-408. 10.4330\/wjc.v12.i8.373","journal-title":"World J Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/life15050802","article-title":"Empagliflozin leads to faster improvement in arterial stiffness compared to dapagliflozin: a double-blind clinical","volume":"15","author":"Campos EG","year":"2025","unstructured":"Campos EG, P\u00e1ez FG, Becerra CG, et al.. Empagliflozin leads to faster improvement in arterial stiffness compared to dapagliflozin: a double-blind clinical. Life (Basel). 2025, 15:10.3390\/life15050802","journal-title":"Life (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.651","article-title":"Endothelial dysfunction: molecular mechanisms and clinical implications","volume":"5","author":"Wang X","year":"2024","unstructured":"Wang X, He B. Endothelial dysfunction: molecular mechanisms and clinical implications. MedComm (2020). 2024, 5:10.1002\/mco2.651","journal-title":"MedComm (2020)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira MJ","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019, 79:219-30. 10.1007\/s40265-019-1057-0","journal-title":"Drugs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1251798","article-title":"Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients","volume":"14","author":"Danpanichkul P","year":"2023","unstructured":"Danpanichkul P, Manosroi W, Nilsirisuk T, Tosukhowong T. Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients. Front Endocrinol (Lausanne). 2023, 14:10.3389\/fendo.2023.1251798","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne KJ","year":"2025","unstructured":"Mayne KJ, Sardell RJ, Staplin N, et al.. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2025, 40:720-30. 10.1093\/ndt\/gfae203","journal-title":"Nephrol Dial Transplant"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00951-5","article-title":"The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and coronary artery disease: the EMPA-CARD randomized controlled trial","volume":"14","author":"Gohari S","year":"2022","unstructured":"Gohari S, Reshadmanesh T, Khodabandehloo H, et al.. The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and coronary artery disease: the EMPA-CARD randomized controlled trial. Diabetol Metab Syndr. 2022, 14:10.1186\/s13098-022-00951-5","journal-title":"Diabetol Metab Syndr"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54498","article-title":"Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics","volume":"11","author":"Liu Z","year":"2021","unstructured":"Liu Z, Ma X, Ilyas I, et al.. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics. 2021, 11:4502-15. 10.7150\/thno.54498","journal-title":"Theranostics"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad157","article-title":"Empagliflozin improves cardiac energetics during ischaemia\/reperfusion by directly increasing cardiac ketone utilization","volume":"119","author":"Chase D","year":"2023","unstructured":"Chase D, Eykyn TR, Shattock MJ, Chung YJ. Empagliflozin improves cardiac energetics during ischaemia\/reperfusion by directly increasing cardiac ketone utilization. Cardiovasc Res. 2023, 119:2672-80. 10.1093\/cvr\/cvad157","journal-title":"Cardiovasc Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-023-00589-y","article-title":"Myocardial metabolism in heart failure","volume":"20","author":"Ng SM","year":"2023","unstructured":"Ng SM, Neubauer S, Rider OJ. Myocardial metabolism in heart failure. Curr Heart Fail Rep. 2023, 20:63-75. 10.1007\/s11897-023-00589-y","journal-title":"Curr Heart Fail Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02879-w","article-title":"Safety of empagliflozin: an individual participant-level data meta-analysis from four large trials","volume":"41","author":"Wanner C","year":"2024","unstructured":"Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, Pfarr E. Safety of empagliflozin: an individual participant-level data meta-analysis from four large trials. Adv Ther. 2024, 41:2826-44. 10.1007\/s12325-024-02879-w","journal-title":"Adv Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01329-7","article-title":"Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus","volume":"37","author":"Schorling OK","year":"2020","unstructured":"Schorling OK, Clark D, Zwiener I, Kaspers S, Lee J, Iliev H. Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus. Adv Ther. 2020, 37:3463-84. 10.1007\/s12325-020-01329-7","journal-title":"Adv Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012843","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials","volume":"97","author":"Zhang YJ","year":"2018","unstructured":"Zhang YJ, Han SL, Sun XF, et al.. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018, 97:10.1097\/MD.0000000000012843","journal-title":"Medicine (Baltimore)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary","volume":"9","author":"Mascolo A","year":"2022","unstructured":"Mascolo A, Di Napoli R, Balzano N, et al.. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary. Front Cardiovasc Med. 2022, 9:10.3389\/fcvm.2022.1010693","journal-title":"Front Cardiovasc Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394397-empagliflozin-and-cardiovascular-outcomes-a-systematic-review-of-randomized-controlled-trials-in-populations-with-diabetes-and-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T13:33:09Z","timestamp":1755264789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394397-empagliflozin-and-cardiovascular-outcomes-a-systematic-review-of-randomized-controlled-trials-in-populations-with-diabetes-and-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.90150","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}